However, another point worthy of note is that PYY3-36-monotherapy treated animals did not show alterations of caloric intake and body weight compared to respective control [31] but presented with mitigated NAFLD as well—a novel finding, which we will pursue in the future using a high-affinity Y2-receptor-agonist. The gene discussed is PYY3; the disease is metabolic dysfunction-associated steatotic liver disease.